You just read:

Novel Preclinical Studies with MabVax Therapeutics' HuMab-5B1 Antibody and HuMab-GD2 Antibodies Presented at the 2017 World Molecular Imaging Congress

News provided by

MabVax Therapeutics Holdings, Inc.

Oct 03, 2017, 08:00 ET